Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer
NCT ID: NCT00004471
Last Updated: 2011-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
9 participants
INTERVENTIONAL
1995-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Determine whether copies of the cystic fibrosis gene (pGT-1) can be delivered to the cells lining the nose of cystic fibrosis patients using cationic liposome (DMRIE/DOPE) mediated gene transfer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis
NCT00004806
IGF-1 Therapy in Patients With Cystic Fibrosis
NCT00566241
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230
Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
NCT00970346
Single Dose of pGM169/GL67A in CF Patients
NCT00789867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are followed daily for 7 days, twice a week for 3 weeks, every 2-3 weeks for 10 weeks, then every 3 months thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pGT-1 gene lipid complex
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not pregnant Fertile patients must use effective contraception
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alabama at Birmingham
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric J. Sorscher
Role: STUDY_CHAIR
University of Alabama at Birmingham
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UAB-6097
Identifier Type: -
Identifier Source: secondary_id
UAB-F930923001
Identifier Type: -
Identifier Source: secondary_id
199/13941
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.